Thus similar to skin inoculation, intranasal delivery of LNPs leads to massive inflammation. Furthermore, the LNPs' inflammatory properties are not site-specific; and show a fast diffusion, dispersion and distribution rate in the (other) tissues.
The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory














